{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:01:45Z","timestamp":1793674905032,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["NRF-CRP25-2020-0003"],"award-info":[{"award-number":["NRF-CRP25-2020-0003"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001271-00"],"award-info":[{"award-number":["MOH-001271-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-000617-00"],"award-info":[{"award-number":["MOH-000617-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001633-00"],"award-info":[{"award-number":["MOH-001633-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-024-01903-7","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:02:48Z","timestamp":1736485368000},"page":"374-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5908","authenticated-orcid":false,"given":"Shirin","family":"Kalimuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2913-7591","authenticated-orcid":false,"given":"Christine Y. L.","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne F. Z.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou Kit","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Kunasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice Y. Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy H. L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean X. Y.","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee-Cheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesa","family":"Syenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Qi","family":"Ngoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Zayanah","family":"Hamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-6172","authenticated-orcid":false,"given":"Yan Shan","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9056-3621","authenticated-orcid":false,"given":"Jia Xin","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3876-2209","authenticated-orcid":false,"given":"Jenny G.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-671X","authenticated-orcid":false,"given":"Kuan Rong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Z.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-1544","authenticated-orcid":false,"given":"Eng Eong","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1903_CR1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1903_CR2","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1080\/21645515.2019.1661209","volume":"15","author":"JN Maslow","year":"2019","unstructured":"Maslow, J. N. Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases. Hum. Vaccin. Immunother. 15, 2230\u20132234 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1903_CR3","doi-asserted-by":"crossref","first-page":"1081107","DOI":"10.3389\/fimmu.2022.1081107","volume":"13","author":"SA Plotkin","year":"2023","unstructured":"Plotkin, S. A. Recent updates on correlates of vaccine-induced protection. Front. Immunol. 13, 1081107 (2023).","journal-title":"Front. Immunol."},{"key":"1903_CR4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12109","volume":"255","author":"TJ Braciale","year":"2013","unstructured":"Braciale, T. J. & Hahn, Y. S. Immunity to viruses. Immunol. Rev. 255, 5\u201312 (2013).","journal-title":"Immunol. Rev."},{"key":"1903_CR5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.abf6446","volume":"371","author":"JL Hope","year":"2021","unstructured":"Hope, J. L. & Bradley, L. M. Lessons in antiviral immunity. Science 371, 464\u2013465 (2021).","journal-title":"Science"},{"key":"1903_CR6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.immuni.2023.02.017","volume":"56","author":"M Koutsakos","year":"2023","unstructured":"Koutsakos, M. et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity 56, 879\u201392.e4 (2023).","journal-title":"Immunity"},{"key":"1903_CR7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/s41590-023-01613-y","volume":"24","author":"MM Painter","year":"2023","unstructured":"Painter, M. M. et al. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nat. Immunol. 24, 1711\u20131724 (2023).","journal-title":"Nat. Immunol."},{"key":"1903_CR8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","volume":"2","author":"S Kalimuddin","year":"2021","unstructured":"Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med 2, 682\u2013688.e4 (2021).","journal-title":"Med"},{"key":"1903_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","volume":"9","author":"B Pulendran","year":"2009","unstructured":"Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741\u2013747 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1903_CR10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710\u2013722 (2008).","journal-title":"Immunity"},{"key":"1903_CR11","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","volume":"183","author":"RS Akondy","year":"2009","unstructured":"Akondy, R. S. et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183, 7919\u20137930 (2009).","journal-title":"J. Immunol."},{"key":"1903_CR12","doi-asserted-by":"crossref","first-page":"12794","DOI":"10.1128\/JVI.01160-13","volume":"87","author":"EA James","year":"2013","unstructured":"James, E. A. et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J. Virol. 87, 12794\u201312804 (2013).","journal-title":"J. Virol."},{"key":"1903_CR13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo1303","volume":"7","author":"S Vardhana","year":"2022","unstructured":"Vardhana, S., Baldo, L., Morice, W. G. 2nd & Wherry, E. J. Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci. Immunol. 7, eabo1303 (2022).","journal-title":"Sci. Immunol."},{"key":"1903_CR14","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.immuni.2022.08.008","volume":"55","author":"A Bertoletti","year":"2022","unstructured":"Bertoletti, A., Le Bert, N. & Tan, A. T. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity 55, 1764\u20131778 (2022).","journal-title":"Immunity"},{"key":"1903_CR15","doi-asserted-by":"crossref","first-page":"e02494-19","DOI":"10.1128\/mBio.02494-19","volume":"11","author":"N Mishra","year":"2020","unstructured":"Mishra, N. et al. A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies. mBio 11, e02494-19 (2020).","journal-title":"mBio"},{"key":"1903_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","volume":"9","author":"DB Kum","year":"2020","unstructured":"Kum, D. B. et al. A chimeric yellow fever\u2013Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerg. Microbes Infect. 9, 520\u2013533 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"1903_CR17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41590-024-01787-z","volume":"25","author":"V Fumagalli","year":"2024","unstructured":"Fumagalli, V. et al. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat. Immunol. 25, 633\u2013643 (2024).","journal-title":"Nat. Immunol."},{"key":"1903_CR18","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","volume":"182","author":"LE Yauch","year":"2009","unstructured":"Yauch, L. E. et al. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182, 4865\u20134873 (2009).","journal-title":"J. Immunol."},{"key":"1903_CR19","doi-asserted-by":"crossref","first-page":"e0005329","DOI":"10.1371\/journal.pntd.0005329","volume":"11","author":"N Jain","year":"2017","unstructured":"Jain, N. et al. CD8 T cells protect adult naive mice from JEV-induced morbidity via lytic function. PLoS Negl. Trop. Dis. 11, e0005329 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1903_CR20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"1903_CR21","first-page":"224","volume":"78","author":"GJ Nossal","year":"2000","unstructured":"Nossal, G. J. Inactivated measles vaccine and the risk of adverse events. Bull. World Health Organ. 78, 224\u2013225 (2000).","journal-title":"Bull. World Health Organ."},{"key":"1903_CR22","doi-asserted-by":"crossref","first-page":"1135979","DOI":"10.3389\/fimmu.2023.1135979","volume":"14","author":"S Kalimuddin","year":"2023","unstructured":"Kalimuddin, S. et al. An experimental medicine decipher of a minimum correlate of cellular immunity: study protocol for a double-blind randomized controlled trial. Front. Immunol. 14, 1135979 (2023).","journal-title":"Front. Immunol."},{"key":"1903_CR23","volume":"1","author":"KR Chan","year":"2016","unstructured":"Chan, K. R. et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat. Microbiol. 1, 16164 (2016).","journal-title":"Nat. Microbiol."},{"key":"1903_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4161\/hv.6.11.12854","volume":"6","author":"PE Nasveld","year":"2010","unstructured":"Nasveld, P. E. et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum. Vaccin. 6, 906\u2013914 (2010).","journal-title":"Hum. Vaccin."},{"key":"1903_CR25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","volume":"20","author":"TP Monath","year":"2002","unstructured":"Monath, T. P. et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004\u20131018 (2002).","journal-title":"Vaccine"},{"key":"1903_CR26","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","volume":"113","author":"L Priyamvada","year":"2016","unstructured":"Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl Acad. Sci. USA 113, 7852\u20137857 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1903_CR27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg9478","volume":"13","author":"LC Katzelnick","year":"2021","unstructured":"Katzelnick, L. C. et al. Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Sci. Transl. Med. 13, eabg9478 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1903_CR28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.1993.1015","volume":"192","author":"JJ Schlesinger","year":"1993","unstructured":"Schlesinger, J. J., Foltzer, M. & Chapman, S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192, 132\u2013141 (1993).","journal-title":"Virology"},{"key":"1903_CR29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/jvi.60.3.1153-1155.1986","volume":"60","author":"JJ Schlesinger","year":"1986","unstructured":"Schlesinger, J. J., Brandriss, M. W., Cropp, C. B. & Monath, T. P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60, 1153\u20131155 (1986).","journal-title":"J. Virol."},{"key":"1903_CR30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.abb9425","volume":"371","author":"N Modhiran","year":"2021","unstructured":"Modhiran, N. et al. A broadly protective antibody that targets the flavivirus NS1 protein. Science 371, 190\u2013194 (2021).","journal-title":"Science"},{"key":"1903_CR31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1126\/science.abc0476","volume":"371","author":"SB Biering","year":"2021","unstructured":"Biering, S. B. et al. Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction. Science 371, 194\u2013200 (2021).","journal-title":"Science"},{"key":"1903_CR32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2020.00334","volume":"11","author":"APS Rathore","year":"2020","unstructured":"Rathore, A. P. S. & St John, A. L. Cross-reactive immunity among flaviviruses. Front. Immunol. 11, 334 (2020).","journal-title":"Front. Immunol."},{"key":"1903_CR33","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/s41564-024-01668-z","volume":"9","author":"AT Waickman","year":"2024","unstructured":"Waickman, A. T. et al. Low-dose dengue virus 3 human challenge model: a phase 1 open-label study. Nat. Microbiol 9, 1356\u20131367 (2024).","journal-title":"Nat. Microbiol"},{"key":"1903_CR34","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.cell.2022.10.023","volume":"185","author":"T Singh","year":"2022","unstructured":"Singh, T. et al. A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. Cell 185, 4826\u201340.e17 (2022).","journal-title":"Cell"},{"key":"1903_CR35","doi-asserted-by":"crossref","first-page":"e1011616","DOI":"10.1371\/journal.ppat.1011616","volume":"19","author":"AD Wegman","year":"2023","unstructured":"Wegman, A. D. et al. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog. 19, e1011616 (2023).","journal-title":"PLoS Pathog."},{"key":"1903_CR36","doi-asserted-by":"crossref","first-page":"e152379","DOI":"10.1172\/JCI152379","volume":"131","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J. Clin. Invest. 131, e152379 (2021).","journal-title":"J. Clin. Invest."},{"key":"1903_CR37","doi-asserted-by":"crossref","first-page":"e96031","DOI":"10.1172\/jci.insight.96031","volume":"2","author":"CY Chan","year":"2017","unstructured":"Chan, C. Y. et al. Early molecular correlates of adverse events following yellow fever vaccination. JCI Insight 2, e96031 (2017).","journal-title":"JCI Insight"},{"key":"1903_CR38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","volume":"66","author":"TP Monath","year":"2002","unstructured":"Monath, T. P. et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66, 533\u2013541 (2002).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1903_CR39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","volume":"188","author":"TP Monath","year":"2003","unstructured":"Monath, T. P. et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213\u20131230 (2003).","journal-title":"J. Infect. Dis."},{"key":"1903_CR40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116\u2013125 (2009).","journal-title":"Nat. Immunol."},{"key":"1903_CR41","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41591-024-02962-3","volume":"30","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y. et al. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children. Nat. Med. 30, 1373\u20131383 (2024).","journal-title":"Nat. Med."},{"key":"1903_CR42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","volume":"601","author":"L Swadling","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"1903_CR43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","volume":"2","author":"F Guirakhoo","year":"2006","unstructured":"Guirakhoo, F. et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2, 60\u201367 (2006).","journal-title":"Hum. Vaccin."},{"key":"1903_CR44","first-page":"e00804","volume":"7","author":"LA Byk","year":"2016","unstructured":"Byk, L. A. et al. Dengue virus genome uncoating requires ubiquitination. mBio 7, e00804\u2013e00816 (2016).","journal-title":"mBio"},{"key":"1903_CR45","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha, N., Harmand, T. J. & Ploegh, H. L. A guide to antigen processing and presentation. Nat. Rev. Immunol. 22, 751\u2013764 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1903_CR46","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1128\/JVI.77.12.7143-7149.2003","volume":"77","author":"CT Jones","year":"2003","unstructured":"Jones, C. T. et al. Flavivirus capsid is a dimeric alpha-helical protein. J. Virol. 77, 7143\u20137149 (2003).","journal-title":"J. Virol."},{"key":"1903_CR47","doi-asserted-by":"crossref","first-page":"e00089-20","DOI":"10.1128\/JVI.00089-20","volume":"94","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species. J. Virol. 94, e00089-20 (2020).","journal-title":"J. Virol."},{"key":"1903_CR48","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1073\/pnas.1500475112","volume":"112","author":"RS Akondy","year":"2015","unstructured":"Akondy, R. S. et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc. Natl Acad. Sci. USA 112, 3050\u20133055 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1903_CR49","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3389\/fimmu.2020.01836","volume":"11","author":"A Stryhn","year":"2020","unstructured":"Stryhn, A. et al. A systematic, unbiased mapping of CD8+ and CD4+ T cell epitopes in yellow fever vaccinees. Front. Immunol. 11, 1836 (2020).","journal-title":"Front. Immunol."},{"key":"1903_CR50","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/v12111300","volume":"12","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Identification of novel yellow fever class II epitopes in YF-17D vaccinees. Viruses 12, 1300 (2020).","journal-title":"Viruses"},{"key":"1903_CR51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"SM Kaech","year":"2002","unstructured":"Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251\u2013262 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"1903_CR52","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02893-20","volume":"59","author":"R Medialdea-Carrera","year":"2021","unstructured":"Medialdea-Carrera, R. et al. A systematic evaluation of IgM and IgG antibody assay accuracy in diagnosing acute Zika virus infection in Brazil: lessons relevant to emerging infections. J. Clin. Microbiol. 59, e0289320 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"1903_CR53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMoa2000226","volume":"383","author":"JG Low","year":"2020","unstructured":"Low, J. G. et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N. Engl. J. Med. 383, 452\u2013459 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1903_CR54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/JCM.02735-14","volume":"53","author":"DY Chao","year":"2015","unstructured":"Chao, D. Y., Galula, J. U., Shen, W. F., Davis, B. S. & Chang, G. J. Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans. J. Clin. Microbiol. 53, 557\u2013566 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"1903_CR55","doi-asserted-by":"crossref","first-page":"e3000867","DOI":"10.1371\/journal.pbio.3000867","volume":"18","author":"E Kudo","year":"2020","unstructured":"Kudo, E. et al. Detection of SARS-CoV-2 RNA by multiplex RT-qPCR. PLoS Biol. 18, e3000867 (2020).","journal-title":"PLoS Biol."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01903-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01903-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01903-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T18:03:20Z","timestamp":1738605800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01903-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1038\/s41564-024-01903-7","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. and J.G.L. have served in advisory capacities for Takeda on dengue. A.B. is co-founder of T Cell Diagnostics, a company developing virus-specific T cell assays. E.E.O. has served in various advisory capacities for Sanofi Pasteur, Takeda, MSD, Janssen Pharmaceuticals, Novartis and Arcturus Therapeutics on dengue and vaccines. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}